BridgeBio Oncology Therapeutics, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2024 | $-618.0K | $-618.0K | — | $39.4K |
| Jun 2024 | $-29.1K | $-29.1K | — | $77.4K |
| Sep 2024 | $-39.3M | $-39.3M | — | $77.4K |
| Mar 2025 | $-19.6M | $-19.8M | $162.0K | $627.0K |
| Jun 2025 | $-23.3M | $-23.5M | $231.0K | $36.0K |
| Sep 2025 | $-28.8M | $-28.9M | $140.0K | — |
| Mar 2026 | $-35.9M | $-35.9M | $24.0K | $3.9M |
| Jun 2026 | $-44.4M | $-44.4M | $47.0K | — |